| Kelan Richard Koenig, MD | |
|
1035 116th Ave Ne, Bellevue, WA 98004-4604 | |
| (425) 688-5972 | |
| Not Available |
| Full Name | Kelan Richard Koenig |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 29 Years |
| Location | 1035 116th Ave Ne, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689699035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00035403 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Overlake Medical Clinics Llc | 7012808827 | 350 |
News Archive
The court's unanimous ruling rejected the arguments advanced by 18 hospitals that sought to reopen a set of Medicare claims that were more than 25 years old.
Multiple human deaths may be required to force the adoption of higher standards in computer software development unless the international software engineering sector lifts its game according UTS IT expert Associate Professor John Leaney.
LUNGevity Foundation, the nation's largest lung cancer organization and the Vanderbilt-Ingram Cancer Center are hosting 75 lung cancer survivors and caregivers tomorrow evening during the first Nashville "Breathe Hope" event, November 5 at the University Club of Nashville from 6:00 p.m. – 8:00 p.m.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
› Verified 5 days ago
| Entity Name | King County Public Hospital District No 2 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801986070 PECOS PAC ID: 7618880097 Enrollment ID: O20031111000557 |
News Archive
The court's unanimous ruling rejected the arguments advanced by 18 hospitals that sought to reopen a set of Medicare claims that were more than 25 years old.
Multiple human deaths may be required to force the adoption of higher standards in computer software development unless the international software engineering sector lifts its game according UTS IT expert Associate Professor John Leaney.
LUNGevity Foundation, the nation's largest lung cancer organization and the Vanderbilt-Ingram Cancer Center are hosting 75 lung cancer survivors and caregivers tomorrow evening during the first Nashville "Breathe Hope" event, November 5 at the University Club of Nashville from 6:00 p.m. – 8:00 p.m.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
› Verified 5 days ago
| Entity Name | Overlake Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861432726 PECOS PAC ID: 9234023433 Enrollment ID: O20040210000160 |
News Archive
The court's unanimous ruling rejected the arguments advanced by 18 hospitals that sought to reopen a set of Medicare claims that were more than 25 years old.
Multiple human deaths may be required to force the adoption of higher standards in computer software development unless the international software engineering sector lifts its game according UTS IT expert Associate Professor John Leaney.
LUNGevity Foundation, the nation's largest lung cancer organization and the Vanderbilt-Ingram Cancer Center are hosting 75 lung cancer survivors and caregivers tomorrow evening during the first Nashville "Breathe Hope" event, November 5 at the University Club of Nashville from 6:00 p.m. – 8:00 p.m.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
› Verified 5 days ago
| Entity Name | Overlake Medical Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
The court's unanimous ruling rejected the arguments advanced by 18 hospitals that sought to reopen a set of Medicare claims that were more than 25 years old.
Multiple human deaths may be required to force the adoption of higher standards in computer software development unless the international software engineering sector lifts its game according UTS IT expert Associate Professor John Leaney.
LUNGevity Foundation, the nation's largest lung cancer organization and the Vanderbilt-Ingram Cancer Center are hosting 75 lung cancer survivors and caregivers tomorrow evening during the first Nashville "Breathe Hope" event, November 5 at the University Club of Nashville from 6:00 p.m. – 8:00 p.m.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelan Richard Koenig, MD 1035 116th Ave Ne, Bellevue, WA 98004-4604 Ph: (425) 688-5972 | Kelan Richard Koenig, MD 1035 116th Ave Ne, Bellevue, WA 98004-4604 Ph: (425) 688-5972 |
News Archive
The court's unanimous ruling rejected the arguments advanced by 18 hospitals that sought to reopen a set of Medicare claims that were more than 25 years old.
Multiple human deaths may be required to force the adoption of higher standards in computer software development unless the international software engineering sector lifts its game according UTS IT expert Associate Professor John Leaney.
LUNGevity Foundation, the nation's largest lung cancer organization and the Vanderbilt-Ingram Cancer Center are hosting 75 lung cancer survivors and caregivers tomorrow evening during the first Nashville "Breathe Hope" event, November 5 at the University Club of Nashville from 6:00 p.m. – 8:00 p.m.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
› Verified 5 days ago
Ted W Farrand, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13451 Se 36th St, Bellevue, WA 98006 Phone: 425-562-1337 Fax: 425-562-1331 | |
Dr. Ashok Shimoji-krishnan, MD, MPH Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13451 Se 36th St, Bellevue, WA 98006 Phone: 425-562-1337 Fax: 425-562-3802 | |
Dr. Romelia Perez, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1611 116th Ave Ne, Suite 132, Bellevue, WA 98004 Phone: 206-795-9797 | |
Dr. Richard Cecil Geary Iii, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1750 112th Ave Ne, B102, Bellevue, WA 98004 Phone: 425-688-5460 Fax: 425-739-4667 | |
Dr. Edward William Freedman, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 1621 114th Ave Se, Suite 221, Bellevue, WA 98004 Phone: 425-455-9900 Fax: 425-688-9987 | |
Ms. Claire Pastor, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1400 112th Ave Se Ste 100, Bellevue, WA 98004 Phone: 425-462-9511 Fax: 425-462-8894 | |
Dr. Megan Christine Riddle, MD PHD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1231 116th Ave Ne Ste 350, Bellevue, WA 98004 Phone: 425-454-1010 Fax: 425-880-5816 |